Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 18.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
| 30.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Unternehmen & Branche
| Name | Protara Therapeutics, Inc. |
|---|---|
| Ticker | TARA |
| CIK | 0001359931 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 195,6 Mio. USD |
| Beta | 1,50 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -57,439,000 | -1.34 | 209,468,000 | 196,412,000 | |
| 2025-09-30 | 10-Q | -13,258,000 | -0.31 | 144,636,000 | 132,291,000 | |
| 2025-06-30 | 10-Q | -14,960,000 | -0.35 | 156,933,000 | 144,423,000 | |
| 2025-03-31 | 10-Q | -11,914,000 | -0.29 | 168,559,000 | 158,484,000 | |
| 2024-12-31 | 10-K | -44,596,000 | -2.17 | 181,454,000 | 167,134,000 | |
| 2024-09-30 | 10-Q | -11,219,000 | -0.50 | 94,090,000 | 81,791,000 | |
| 2024-06-30 | 10-Q | -9,513,000 | -0.45 | 101,647,000 | 92,050,000 | |
| 2024-03-31 | 10-Q | -11,095,000 | -0.97 | 68,134,000 | 58,406,000 | |
| 2023-12-31 | 10-K | -40,420,000 | -3.57 | 78,954,000 | 68,321,000 | |
| 2023-09-30 | 10-Q | -9,860,000 | -0.87 | 88,467,000 | 76,956,000 | |
| 2023-06-30 | 10-Q | -11,294,000 | -1.00 | 95,141,000 | 85,225,000 | |
| 2023-03-31 | 10-Q | -9,045,000 | -0.80 | 106,405,000 | 94,768,000 | |
| 2022-12-31 | 10-K | -65,952,000 | -5.86 | 113,290,000 | 102,083,000 | |
| 2022-09-30 | 10-Q | -7,691,000 | -0.68 | 148,591,000 | 139,178,000 | |
| 2022-06-30 | 10-Q | -8,539,000 | -0.76 | 154,884,000 | 145,458,000 | |
| 2022-03-31 | 10-Q | -10,755,000 | -0.96 | 161,256,000 | 152,235,000 | |
| 2021-12-31 | 10-K | -47,252,000 | -4.21 | 172,596,000 | 161,914,000 | |
| 2021-09-30 | 10-Q | -10,777,000 | -0.96 | 180,697,000 | 170,406,000 | |
| 2021-06-30 | 10-Q | -12,782,000 | -1.14 | 188,892,000 | 178,405,000 | |
| 2021-03-31 | 10-Q | -13,465,000 | 192,413,000 | 188,126,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Zummo Jacqueline | Officer, Chief R&D Officer | Open Market Sale | -1,134 | 5.40 | -6,123.60 | -13,7% | |
| 2025-05-14 | Levy Richard S | Director | Open Market Purchase | 20,000 | 3.19 | 63,800.00 | +143,1% | |
| 2025-05-14 | Levy Richard S | Director | Open Market Purchase | 20,000 | 3.19 | 63,800.00 | +143,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.